English
Spanish
French
Italian
German
NEWS
Latest News
Spironolactone for Hidradenitis Suppurativa: A Game-Changer for Women of Childbearing Age?
June 30, 2025
Could spironolactone be a game-changer for women with early-stage HS? A recent study found that while only 1 in 5 women of childbearing age saw improvement with the hormone-blocking drug, those with milder disease and earlier treatment were far more likely to benefit. This research offers valuable insight into tailoring HS treatment for patients most likely to respond.
Read more
Deroofing – Safe and Effective for HS Patients
June 18, 2025
A new study highlights the safety and effectiveness of deroofing—a surgical treatment for hidradenitis suppurativa. Among 44 patients, only 12% of lesions returned within a year, and most reported less pain and better quality of life. While further research is needed, these results suggest deroofing may be a valuable option, even alongside systemic therapies.
Read more
Semaglutide for diabetes, weight loss, and… Hidradenitis Suppurativa?
April 28, 2025
Could a popular weight loss and diabetes drug also help treat hidradenitis suppurativa? See what researchers discovered about semaglutide’s surprising potential.
Read more
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppura
March 18, 2025
Incyte announced positive Phase 3 results for povorcitinib in hidradenitis suppurativa, with both trials meeting their primary endpoint of reducing inflammatory nodules.
Read more
Links Between Plastics Use, Processed Food, Sweating, and Hidradenitis Suppurativa
March 5, 2025
Could everyday habits like diet, plastic use, and sweating play a role in HS? This study uncovers intriguing connections that may shape our understanding of the condition.
Read more
SHSA 2024 Abstracts Now Published in Dermatology and Therapy!
February 19, 2025
The research presented at SHSA 2024 is now accessible to the global dermatology community! Explore the latest findings in Hidradenitis Suppurativa, now published in Dermatology and Therapy.
Read more
British Journal of Dermatology Releases Hidradenitis Suppurativa Supplement
February 5, 2025
The British Journal of Dermatology has released a comprehensive Hidradenitis Suppurativa Supplement in its February 2025 issue. This special edition features state-of-the-art reviews and research articles from leading experts, offering new insights into disease mechanisms, treatment options, and patient care strategies. Explore the latest advancements in understanding and managing this chronic skin condition.
Read more
North American Clinical Practice Guidelines for the Medical Management of Hidradenitis Suppurativa in Special Patient Population
January 14, 2025
New evidence-based guidelines are now available to help clinicians manage Hidradenitis Suppurativa in vulnerable populations, including women, adolescents, and individuals with chronic conditions. This important resource is made possible by the hard work of many individuals, including several current HS Foundation leaders.
Read more
Hidradenitis Suppurativa and Maternal and Offspring Outcomes
January 9, 2025
How does Hidradenitis Suppurativa during pregnancy impact the health of mothers and their newborns both immediately and long-term?
Read more
Analysis of ChatGPT’s Responses to Patient Questions on Hidradenitis Suppurativa
January 8, 2025
A recent study revealed that while AI tools like ChatGPT can provide health information, responses from the HS Foundation website are more readable, accurate, and reliable for patients seeking guidance. This information emphasizes that relying on AI for medical advice can come with risks, as it may lack the clarity and nuance provided by expert-reviewed resources. At HSF, we are dedicated to being the world's most trusted resource for expert information on HS, empowering patients and providers with accurate, evidence-based insights.
Read more
UCSF-led Study Aims to Improve Treatment of Painful Skin Disease
December 18, 2024
HS Foundation Vice President, Dr. Haley Naik, just announced a collaboration with UCB USA and UCSF -led HS PROGRESS (Hidradenitis Suppurativa PRospective Observational REgistry and bioSpecimen repoSitory).
This collaboration will help support the registry's efforts to accelerate development of treatment options for the condition. The HSF is proud to have provided seed funding for HS PROGRESS from 2020-2022, and we are excited to see the widespread positive impact this resource will have on the entire HS community.
Read more
Hidradenitis suppurativa: Embracing progress
December 1, 2024
The HS Foundation has partnered with the AAD Member to publish "Hidradenitis Suppurativa: Embracing Progress" in the December issue of the Journal of the American Academy of Dermatology (JAAD).
This supplement highlights the latest advancements in HS research and care. While JAAD content is typically available to subscribers only, our partnership ensures this supplement is free to access for everyone for the next six months!
HSF Board Members Drs. Chris Sayed and Jennifer Hsiao served as co-editors on the supplement, which features content submitted by many HS Foundation leaders and volunteers.
Read more
UCB receives U.S. FDA approval for BIMZELX[®] (bimekizumab-bkzx) as the first IL-17A and IL-17F inhibitor for adults with modera
November 20, 2024
This week, the FDA announced the approval of bimekizumab-bkzx (Bimzelx), developed by UCB USA, for the treatment of moderate to severe Hidradenitis Suppurativa (HS) in adults. Bimzelx is the first dual IL-17 inhibitor approved for HS, marking a groundbreaking step forward in treatment options. This is the third FDA-approved therapy for HS—and the second in just 13 months—signaling incredible momentum in research and care for those living with HS.
Read more
American Academy of Dermatology launches innovative project to improve outcomes for patients with hidradenitis suppurativa
October 30, 2024
The American Academy of Dermatology (AAD) has launched a groundbreaking initiative to improve outcomes for those living with Hidradenitis Suppurativa (HS). By focusing on education, collaboration, and best practices, this project aims to empower dermatologists and enhance patient care.
Read more
UNC School of Medicine Researchers Take on Chronic Skin Condition
October 7, 2024
HS Foundation Board Member, Dr. Christopher Sayed from the UNC Department of Dermatology, along with his collaborates, Drs. Karen Mohlke and Yun Li from the UNC Department of Genetics, recently received $2.3 million in research funding to continue their work studying the genetics of Hidradenitis Suppurativa (HS).
Their previous researched discovered genetic changes that seem to increase the risk of developing HS near the genes SOX9 and KLF5. These genes help to control stem cells in the hair follicles that are important for regulating wound healing and inflammation.
Now, they’re diving deeper to uncover additional genes that might contribute to developing HS and understanding how changes in their behavior lead to the development of HS.
Read more
Dermatology Research Team Investigating the Most Common Disease You’ve Never Heard About
September 20, 2024
Researchers at the University of Miami’s Miller School, including HS Foundation President Dr. Hadar Lev-Tov, as well as Drs. Irena Pastar and Marjana Tomic-Canic, have been awarded a $2.2M NIH RO1 grant for a five-year translational study.
Read more
Advances in HS Pathogenesis and Therapies from SHSA 2023 Published in the Journal of Investigative Dermatology
July 23, 2024
SHSA 2023 Findings Published in JID
Read more
Benefits of the Mediterranean Diet and Physical Activity in HS
January 2, 2024
Can Diet and Physical Activity Improve Your HS?
Read more
Barriers to Accessing Care for HS
September 7, 2023
Patient interviews highlight challenges in accessing HS care
Read more
Genetic Variants Associated with Hidradenitis Suppurativa
August 27, 2023
Two genes identified as likely associates with HS
Read more
Assessing the Impact of HS on Work Productivity
August 22, 2023
Study demonstrates decrease in work productivity due to HS
Read more
What is Pain Really Like for People with HS
June 8, 2023
Initial HS lesions present with itch, but can progress to pain.
Read more
Average Time Patients Stay on Biologic Treatment
June 8, 2023
Study Shows Treatment of HS is Challenging
Read more
Bimekizumab and HS
May 3, 2023
Safe and Effective Results Shown with Bimekizumab in Phase II Studies
Read more
Birth Control and HS
April 11, 2023
Small study shows birth control pills may be useful in the treatment of HS
Read more
Benefits of Finasteride in Women with HS
March 9, 2023
Can finasteride help control hidradenitis suppurativa in women?
Read more
Biologic Therapy Not Associated with COVID-19 Severity
February 1, 2023
Biologic Therapy Not Linked to COVID-19 Severity in People With HS
Read more
HS Foundation’s HS CAPE (Community Awareness and Patient Empowerment) Program Request for Proposals
January 9, 2023
The goal of the CAPE grant is to stimulate the development of programs that increase disease awareness, provide support to patients and caregivers, improve patient care or benefit patients with HS in other ways. Typical awards will be for up to $2,000 but proposals for up to $5,000 will be considered (direct costs only, regardless of the amount of the award). Award amount is contingent upon the availability of funds and the receipt of sufficiently meritorious applications.
Read more
Interview with 2021 HSF Danby Grant Recipient Dr. Carmelo Carmona-Rivera, PhD
December 1, 2022
Learn about 2021 Danby Grant Recipient Dr. Carmelo Carmona-Rivera, PhD and his winning project which aimed to find disease-causing interactions between cells or between cells and NETs.
Read more
Interview with 2017 HSF Danby Grant Recipient Amanda Nelson, PhD
December 1, 2022
Learn about 2017 Danby Grant Recipient Amanda Nelson, PhD and her winning project which investigated whether skin stem cells were misplaced and abnormally active in HS lesions.
Read more
Adalimumab (Humira) in combination with surgery is safe and effective to treat hidradenitis suppurativa.
December 1, 2022
This study explored whether it was safe for patients to undergo skin surgery while on adalimumab.
Read more
A new treatment option for tunnels in HS
December 1, 2022
An Open-Label, Prospective, Pilot Study of Hypertonic Saline for Hidradenitis Suppurativa.
Read more
Interview with 2018 HSF Danby Grant Recipient Angel Byrd, MD PhD
October 4, 2022
Learn about Danby Grant Recipient Angel Byrd, MD PhD and her winning project which aimed to establish a biorepository of HS tissue samples to better understand the disease.
Read more
Interview with 2020 HSF Danby Grant Recipient Dr. Lauren Orenstein
October 4, 2022
Learn about Dr. Lauren Orenstein's Danby Award-winning project which studied patterns of health care utilization and opioid prescription use among patients with hidradenitis suppurativa.
Read more
HSF Career Development Award through the Dermatology Foundation
September 26, 2022
Career Development Award
Read more
2019 HSF Danby Grant Awardee Dr. Abrar Qureshi Interview
August 9, 2022
HSF Danby Grant Funding Helps Develop a Useful Screening Tool for HS
Read more
View the latest research summary from the HS Foundation
August 4, 2022
A number of medical conditions are associated with HS - what are they?
Read more
Factors that affect delayed HS diagnosis in children and teenagers
June 21, 2022
What happens if hidradenitis suppurativa (HS) diagnosis is delayed in children?
Read more
2022 Danby Awards
June 3, 2022
The HSF is pleased to announce the awarding of four Danby Research Grants in 2022, the most ever offered by the Foundation. These researchers are proposing exciting research initiatives in HS.
Read more
Interview with 2018 Danby Grant Recipient Dr. Tina Porter
June 3, 2022
Dr. Alexander Charrow interviews Dr. Tina Porter, assistant professor at Harvard Medical School and 2018 Danby Grant Recipient, about her research on treating hidradenitis tunnels.
Read more
HS surgeries associated with high satisfaction, brief recovery and tolerable pain
June 2, 2022
Considering surgery for treating hidradenitis suppurativa (HS) can feel intimidating, especially because it can be hard to know what to expect.
Read more
Negative Impacts of Hidradenitis Suppurativa in Pregnant Women
June 2, 2022
Women with HS were more likely to have health problems before pregnancy compared to women without HS.
Read more
An Interview with 2019 Danby Research Grant Awardee John Frew, MBBS, PhD
June 2, 2022
Get to know the 2019 recipient and how his project aimed to identify potential clinical and therapeutic biomarkers of HS disease activity.
Read more
HSF Installs New Officers and Board Members at its March Board Meeting
April 6, 2022
During the recently held American Academy of Dermatology annual meeting in Boston, the HSF Board of Directors met and installed three new board members, as well as new officers. Dr. Joslyn Kirby will serve a two-year term as president.
Read more
A Deep Look at the Bacteria Living in Patients with HS
February 28, 2022
This research study explored the differences in the microbiome between unaffected individuals and those with HS by obtaining bacterial swabs from the skin, inside the nose, and stool from both groups.
Read more
Can Hidradenitis Suppurativa Affect Pregnancy?
August 30, 2021
Research on how HS affects pregnancy is limited, which is what led researchers at Penn State College of Medicine to perform a study that compared pregnancy outcomes in patients with and without HS.
Read more
Hidradenitis Suppurativa Foundation Danby Research Grants
May 25, 2021
For the past five years, the Hidradenitis Suppurativa Foundation (HSF) has proudly sponsored up to $10,000 for research projects that will have a sustained, powerful influence on our understanding of hidradenitis suppurativa (HS).
Read more
Clinical Epidemiology and Management of Hidradenitis Suppurativa
April 1, 2021
Understanding hidradenitis suppurativa clinical epidemiology and management facilitates early diagnosis and treatment, thereby reducing morbidity with the potential to favorably alter disease trajectory.
Read more
How should Pregnant and Nursing Mothers manage Hidradenitis Suppurativa?
February 28, 2021
With a growing need to properly manage HS in pregnant and nursing mothers, here we discuss the article “Management of Hidradenitis Suppurativa in Pregnancy” published in 2017 that provides the most up-to-date information.
Read more
How clear is the link between Hidradenitis Suppurativa and Inflammatory Bowel Disease?
February 19, 2021
Some research studies showed the HS and IBD are more likely to happen together, but two other studies did not show a link between them. The goal of this study was to combine all of the best studies and try to clear up whether there is a link between HS and IBD.
Read more
Comorbidity screening in hidradenitis suppurativa
January 22, 2021
Systematic reviews were performed to summarize evidence on the prevalence and incidence of 30 comorbidities in patients with HS relative to the general population.
Read more
COVID-19 Vaccines: Information for People with HS & their Caregivers
December 19, 2020
We know that you and your family probably have many questions about the COVID-19 vaccines that are being approved by the U.S. Food and Drug Administration (FDA). We are here to help and provide you with the most current information.
Read more
How are Emergency Departments treating pain in Hidradenitis Suppurativa?
November 18, 2020
For many patients with Hidradenitis Suppurativa (HS), pain is a problem that can lead to visits to the Emergency Department (ED).
Read more
Are people willing to use teledermatology for Hidradenitis Suppurativa care?
June 5, 2020
In new, yet unpublished data from a project by Joslyn Kirby, Ashley Eichelberger, Melissa Butt, Colleen Silva, and Aretha Mosley of Penn State Hershey School of Medicine, patients shared their thoughts and experience about long-distance dermatology visits.
Read more
The Hidden, Common Disease You've Never Heard Of
June 2, 2020
In today’s informed and connected world, it’s hard to believe there might be common diseases that you have never heard of.
Read more
6 Myths about Hidradenitis Suppurativa
June 1, 2020
We addressed 6 myths about Hidradenitis Suppurativa
Read more
Is COVID more risky for people treated for an immune disease?
May 22, 2020
In a study led by Dr. Rebecca Haberman of New York University, a group of doctors studied whether people being treated for immune diseases had more severe COVID.
Read more
What is the right dose of infliximab for Hidradenitis Suppurativa?
April 20, 2020
Infliximab is an intravenous (IV) medication that can help Hidradenitis Suppurativa (HS). The dose and timing of infliximab vary. The authors determined which dose was the best when starting treatment for HS.
Read more
Global Registry for Hidradenitis Suppurativa + COVID-19
April 17, 2020
International HS experts have recently established the Global HS COVID-19 Registry to better understand the risk of infection and clinical course of HS patients in the setting of COVID-19.
Read more
Anything new out there to help treat my HS?
April 11, 2020
In recent years, research has led to a deeper understanding of immune imbalances that may lead hidradenitis suppurativa (HS).
Read more
Frequently Asked Questions about Hidradenitis Suppurativa (HS) and COVID-19
April 6, 2020
What is COVID-19, and how is it different from the flu or other infections we have dealt with?
Read more
A new way to measure the extent of patients’ hidradenitis suppurativa
March 31, 2020
This study was done by researchers in the U.S.A. to find how well clinicians could measure HS using a different approach.
Read more
COVID-19 & Hidradenitis Suppurativa Podcast
March 24, 2020
HSF partnered with LearnSkin on a special podcast episode to bring expert insight into what COVID-19 means for dermatologists and their patients with Hidradenitis Suppurativa.
Read more
Plastic Surgical Management of Hidradenitis Suppurativa
March 10, 2020
Successful treatment of hidradenitis suppurativa requires a multidisciplinary team approach and multimodal therapy.
Read more
New drug shows promise for Hidradenitis Suppurativa treatment
February 27, 2020
An early study for bermekimab shows improvement in Hidradenitis Suppurativa (HS) activity and pain scores while demonstrating safety.
Read more
A study into the risk of serious infections in people with hidradenitis suppurativa
February 3, 2020
This study's aim was to determine if associations between HS and various serious infections exist, using the National Inpatient Sample, a USA database of inpatient hospitalizations, between the years 2002 and 2012. The study also looked into the cost of care and length of stay of HS patients with serious infections.
Read more
Pain perception and depression in patients with hidradenitis suppurativa
January 2, 2020
HS causes pain, but few studies have looked at this aspect. The authors aimed to study pain in patients with HS.
Read more
A review of use of the word ‘flare’ in hidradenitis suppurativa studies
January 2, 2020
HS lesions can come-and-go or last for months or years. HS can have times where it is worse than usual. These have been called ‘flares’. To measure flares in future studies, a definition for a flare is needed. This study was done to find out how flares were defined in past studies.
Read more
Incidence of Myocardial Infarction and Cerebrovascular Accident in Patients With Hidradenitis Suppurativa
November 13, 2019
New findings, recently published in JAMA Dermatology, appear to show that having HS confers a modest risk of having a heart attack or a stroke.
Read more
Most Hidradenitis Suppurativa patients improve with infliximab, if the dose is high enough
October 4, 2019
Some Hidradenitis Suppurativa patients improve when they receive infliximab, but we don’t know the proper dose of infliximab to give. This research asked whether high-dose infliximab helps Hidradenitis Suppurativa patients.
Read more
Inter-rater reliability and agreement hidradenitis suppurativa instruments
September 1, 2019
This study aimed to find out how consistently 12 HS-experienced dermatologists would score 24 patients with HS, using nine different instruments.
Read more
Investigation of the skin microbiome
September 1, 2019
Researchers from Sweden, Ireland and the UK looked at the difference between the results of swabs and actual biopsies (tissue samples) of the skin.
Read more
Association between HS and hospitalization for psychiatric disorders
August 1, 2019
The researchers of this study are based in U.S.A. and aimed to find out if hidradenitis is linked with higher likelihood and costs of mental health disorders.
Read more
Inter- and intrarater reliability of Hurley staging
August 1, 2019
This study, which was an international co-operation between departments in Germany, Denmark and Poland, was designed to check the agreement between different dermatologists, including those in training, on their rating of the stage of HS in 5 different patients on two separate occasions.
Read more
Impact of HS on work loss, indirect costs and income
July 1, 2019
This study aimed to find out how the work life of people with HS was impacted compared to similar people without HS.
Read more
Pyrin mutations in complex hidradenitis suppurativa
June 3, 2019
This study, performed by researchers from Turkey and Germany, looked at the role of a gene called MEFV gene in HS, using a group of 119 people with the disease.
Read more
What’s the risk of lymphoma in people with HS?
May 1, 2019
This study was done to look at whether the inflammation from HS might increase the chance that someone’s immune system could go off the rails and cause lymphoma.
Read more
Cost-savings in hidradenitis suppurativa
April 26, 2019
This study, undertaken at the ATTIKON University Hospital of Athens, Greece, suggests adalimumab could be a cost-effective and efficient treatment for HS.
Read more
BAD guidelines for the management of HS (acne inversa) 2018
April 26, 2019
The British Association of Dermatologists commissioned a HS guideline development group composed of information specialists, a HS patient and carer, and UK clinicians including dermatologists, a dermatology nurse, plastic surgeon and general practitioner (GP). The group, based in the UK, were asked to produce treatment recommendations based on a systematic review of the evidence.
Read more
Does Hidradenitis Suppurativa cause skin cancer?
April 1, 2019
Longstanding Hidradenitis Suppurativa (HS) can be associated with other complications, such as intestinal problems and skin cancer.
Read more
Patients with self-reported HS in a cohort of Danish blood donors
April 1, 2019
The unique nature of HS makes it possible to diagnose the disease using questionnaires.
Read more
Illness perceptions and health outcomes in HS
February 4, 2019
In this study from a specialised HS clinic in a large UK hospital, dermatologists collaborated with psychologists to establish for the first time, the relationships between illness perceptions and health outcomes.
Read more
Complement in hidradenitis suppurativa
August 24, 2018
This is a study on the pathogenesis (causes) of hidradenitis suppurativa (HS).
Read more
Imbalanced Th17/Treg axis in hidradenitis suppurativa
August 24, 2018
The aim of this study from the German Universities of Osnabrück and Munich was to clarify whether obesity and smoking promote the Th17/Treg imbalance.
Read more
Hidradenitis suppurativa treated with secukinumab
July 19, 2018
Medications targeting small proteins called cytokines could provide a possible treatment approach for HS in the future.
Read more
Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis
April 18, 2018
Our study team based in the UK aimed to use UK electronic data recorded by General Practitioners (GPs) to identify known and previously undiagnosed cases of HS.
Read more
Prevalence of hidradenitis suppurativa among patients with Down syndrome: a population-based cross-sectional analysis
March 29, 2018
In this study, we evaluated the commonness of hidradenitis suppurativa within a large group of patients who had Down syndrome, and we used another groups of patients that did not have Down syndrome to compare findings.
Read more
Incidence of hidradenitis suppurativa among tobacco smokers: a population-based retrospective analysis in the U.S.A.
March 29, 2018
Despite a common belief that tobacco smoking increases the risk of developing the disease, the evidence linking the two is controversial.
Read more
Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings
March 29, 2018
This study aimed to find out what clinical trials for HS should measure, such as symptoms (e.g. pain, itch), physical changes (e.g. skin redness or swelling), or impact on people's lives (e.g. quality of life).
Read more
Interleukin-36 in hidradenitis suppurativa
March 29, 2018
Scientists from Germany investigated whether a cytokine called interleukin-36 (IL-36) might be important in hidradenitis suppurativa (HS).
Read more
A phenotype combining hidradenitis suppurativa with Dowling–Degos disease caused by a founder mutation in PSENEN
February 18, 2018
In this present study, we showed a new genetic defect in PSENEN that can cause two diseases at once: Dowling-Degos disease and hidradenitis suppurativa.
Read more
Hidradenitis suppurativa and electrocardiographic changes: a cross-sectional population study
January 22, 2018
The aim of this study from Denmark was to investigate this possible cardiovascular burden associated with HS influence on the heart's electrical activity.
Read more
Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa
October 5, 2015
This study, from Germany, sought to identify the cellular sources of IL-17 in HS, and looked at a range of other factors that might contribute to the development of the disease, including the presence and source of other proteins that are involved in HS.
Read more
Diagnostic delay in hidradenitis suppurativa is a global problem
July 21, 2015
In this study, 517 patients with HS and 516 patients with another skin disease, psoriasis, from 24 countries were asked about the time it took to first see a doctor and then receive a diagnosis.
Read more
The Hidradenitis Suppurativa Priority Setting Partnership
June 5, 2014
According to the authors of this study, HS has been relatively neglected by society and medical research funding bodies, resulting in a lack of evidence to guide HS care. A Priority Setting Partnership (PSP) for HS was established following a model created by the James Lind Alliance which helps to bring patients, carers and clinicians together to identify and prioritise for research the treatment uncertainties which they agree are the most important.
Read more